Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Menlo Therapeutics Inc is a biotechnology business based in the US. Menlo Therapeutics shares (MNLO) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$1.7|
|52-week range||USD$1 - USD$7.48|
|50-day moving average||USD$1.7535|
|200-day moving average||USD$1.7704|
|Wall St. target price||USD$8.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.818|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||N/A|
|1 month (2020-11-06)||1.49%|
|3 months (2020-09-02)||N/A|
|6 months (2020-06-02)||N/A|
|1 year (2019-12-02)||N/A|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Revenue TTM||USD$13.6 million|
|Gross profit TTM||USD$443,000|
|Return on assets TTM||-68.11%|
|Return on equity TTM||0%|
|Market capitalisation||USD$226.4 million|
TTM: trailing 12 months
There are currently 11.2 million Menlo Therapeutics shares held short by investors – that's known as Menlo Therapeutics's "short interest". This figure is 62% up from 6.9 million last month.
There are a few different ways that this level of interest in shorting Menlo Therapeutics shares can be evaluated.
Menlo Therapeutics's "short interest ratio" (SIR) is the quantity of Menlo Therapeutics shares currently shorted divided by the average quantity of Menlo Therapeutics shares traded daily (recently around 2.4 million). Menlo Therapeutics's SIR currently stands at 4.59. In other words for every 100,000 Menlo Therapeutics shares traded daily on the market, roughly 4590 shares are currently held short.
However Menlo Therapeutics's short interest can also be evaluated against the total number of Menlo Therapeutics shares, or, against the total number of tradable Menlo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Menlo Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Menlo Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0697% of the tradable shares (for every 100,000 tradable Menlo Therapeutics shares, roughly 70 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Menlo Therapeutics.
Find out more about how you can short Menlo Therapeutics stock.
We're not expecting Menlo Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Menlo Therapeutics's shares have ranged in value from as little as $1 up to $7.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Menlo Therapeutics's is 1.6857. This would suggest that Menlo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.